Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 8/20 | 0.60 |
| ▸ | FAAH | O00519 | 6/20 | 0.60 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.49 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163189 | 0.79 | FAAH (0.53) | CES1FAAHNCEH1 | |
| SCHEMBL2162914 | 0.79 | DAGLA (0.49) | CES1FAAHDAGLANPC1RAB9A | |
| SCHEMBL2162938 | 0.78 | CES1 (0.68) | CES1FAAHNCEH1DAGLA | |
| SCHEMBL2161861 | 0.78 | DAGLA (0.50) | CES1FAAHDAGLANPC1RAB9A | |
| SCHEMBL2163364 | 0.75 | CES1 (1.00) | CES1FAAHNCEH1DAGLA | |
| SCHEMBL2162361 | 0.75 | CES1 (0.60) | CES1FAAH | |
| SCHEMBL2162156 | 0.74 | CES1 (0.44) | CES1FAAHNCEH1DAGLA | |
| SCHEMBL2162939 | 0.72 | CES1 (0.46) | CES1FAAHNCEH1 | |
| SCHEMBL2161919 | 0.72 | CES1 (0.48) | CES1FAAHNCEH1NPC1RAB9A | |
| SCHEMBL2163571 | 0.71 | CES1 (0.53) | CES1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | FAAH, FAAH2, FADS1 | CES1 11/4885FAAH 1/4885NCEH1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.